SCHEMBL8667804

SCHEMBL8667804

CSc1nc2ccc(Cl)cc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
ALDH1A1 P00352 4/20 0.65
HSD17B10 Q99714 3/20 0.57
RAB9A P51151 1/20 0.57
HTR3E A5X5Y0 1/20 0.56
HTR3B O95264 1/20 0.56
HTR3A P46098 1/20 0.56
BACE1 P56817 1/20 0.56
HTR3D Q70Z44 1/20 0.56
HTR3C Q8WXA8 1/20 0.56
MAPT P10636 3/20 0.54
MEN1 O00255 2/20 0.54
CYP3A4 P08684 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 1/20 0.54
TP53 P04637 1/20 0.54
MAPK1 P28482 1/20 0.54
FTO Q9C0B1 1/20 0.54
PSMB8 P28062 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6261732 0.86 SMN1; SMN2 (0.75) HPGDSMN1; SMN2ALDH1A1HSD17B10RAB9A
SCHEMBL17153982 0.85 HPGD (0.74) HPGDSMN1; SMN2ALDH1A1HSD17B10RAB9A
SCHEMBL22962342 0.82 HPGD (0.70) HPGDSMN1; SMN2ALDH1A1HSD17B10RAB9A
SCHEMBL4597364 0.80 ALDH1A1 (0.67) HPGDSMN1; SMN2ALDH1A1HSD17B10RAB9A
SCHEMBL7517182 0.79 HPGD (0.66) HPGDSMN1; SMN2ALDH1A1RAB9AMAPT
SCHEMBL2593902 0.79 ALDH1A1 (0.65) HPGDSMN1; SMN2ALDH1A1HSD17B10RAB9A
SCHEMBL20683082 0.79 HPGD (0.65) HPGDSMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL11106578 0.78 TTR (0.64) HPGDSMN1; SMN2ALDH1A1HSD17B10RAB9A
SCHEMBL13545521 0.77 HPGD (0.62) HPGDSMN1; SMN2HTR3AMAPTMEN1
SCHEMBL14304934 0.77 RAB9A (0.63) HPGDSMN1; SMN2ALDH1A1HSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752498-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2023-06-28 EP disclosed
US-20110245231-A1 ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE ALLA CHEM, LLC (US) 2011-10-06 US disclosed
US-5801180-A ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS EISAI CO., LTD. (JP) 1998-09-01 US disclosed
US-5693652-A Benzimidazoles for ischemic heart conditions EISAI CO., LTD. (JP) 1997-12-02 US disclosed
US-5576322-A Anti-ischemic 2,4-diaminoquinazolines EISAI CO., LTD. (JP) 1996-11-19 US disclosed
EP-0607439-A1 NITROGENOUS HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 1994-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245231-A1 ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE ADH1C, ADH1A, ADH5 HPGD 804/4885SMN1; SMN2 3094/4885ALDH1A1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.